Bruker Corporation Q3 2026 Earnings Webcast - BRUKER CORP

Explicit Guidance:

• FY2026 Reported Revenue: Updated range of $3.52B–$3.56B (previously $3.50B–$3.56B), implying 2.5%–3.5% reported growth vs. FY2025; currency impact expected to be neutral to slightly negative after recent USD strengthening.
• FY2026 Organic Revenue Growth: Reconfirmed range of 1%–2%.
• FY2026 Acquisition Contribution: Expected to be approximately 1.5% of total revenue.
• FY2026 Non-GAAP EPS: Reconfirmed range of $2.10–$2.15, representing 15%–17% growth vs. FY2025; effective tax rate guidance updated to 27.5% (up from 26.5%) due to jurisdictional mix.
• FY2026 Operating Margin: Expectation of 250–300 basis points expansion vs. FY2025, driven by cost-saving initiatives and favorable mix.
• FY2026 Cost Savings: On track to achieve $140M annualized run rate.
• FY2026 Free Cash Flow: Continued deleveraging expected; net leverage ratio projected to remain below 2.5x (was 2.4x as of Sept 30, 2026).
• Q4 FY2026 Organic Revenue: Expected to grow in the lower-mid single-digit percentage year-over-year.
• Q4 FY2026 Margins: Anticipates meaningful sequential and YoY increases in operating margin and EPS driven by volume, mix (including ultra high-field systems), and compounding cost savings.
• FY2027 EPS: Targeting double-digit growth.
• FY2027 Operating Margin: Targeting >100 basis points expansion vs. FY2026.
• FY2027 Organic Revenue Growth: Targeting growth in the "lower-mid single-digit" range (consistent with a potential 4%–5% scenario).
• FY2027 Effective Tax Rate: Target to drive rate down at least 50 basis points year-over-year from the 27.5% FY2026 level.
• FY2027 Guidance Timing: Full-year financial guidance for 2027 will be provided upon Q4 FY2026 results in February 2027.

Business-Segment Outlook:

• BSI (Bio-Solutions Instruments):
  • Backlog: Mid-single-digit organic growth YTD; expected to convert to revenue revenue growth acceleration in FY27.
  • U.S. AcaGov: Double-digit organic bookings growth in Q3 2026 (first YoY growth since 2025 NIH disruption); expectation for YoY organic bookings growth in Q4 2026; potential positive impact from U.S. midterms on FY2027 funding.
  • China BSI: >20% organic bookings growth in Q3 and YTD (broad-based across end markets); trend expected to continue into Q4 2026.
  • Semi-Metrology: >30% organic bookings growth YTD fueled by AI megatrend (logic, HBM, advanced packaging); orders expected to convert to revenue primarily in FY27, with some in FY28; longer lead times than life science tools.
  • NMR/Imaging: Conversion lag expected due to 2025 AcaGov weakness; recovery anticipated to drive FY27 growth.
• BEST (Bio-Science Technologies):
  • Revenue: Up 8.3% CER YTD.
  • Drivers: Strong growth in Research Instruments (RI) and superconductors; specific growth driven by ITER/fusion energy projects, high-energy physics, and ASML lithography supply chain.
  • Outlook: "Very strong" order trends expected to sustain growth.
• Microbiology & Infectious Disease Diagnostics (B-MID):
  • Revenue: Low single-digit growth YTD; "high single-digit" long-term growth rate anticipated.
  • Pipeline: WAVE product (antibiotic susceptibility testing) targeting FDA clearance by end of 2026 or Q1 2027 to strengthen U.S. sepsis testing capabilities.
  • Concurrence: "Genius" platform placements ahead of plan; consumables acceleration expected in 2027 and beyond.
• Acquisitions (MIMETAS):
  • Status: Majority stake acquired in humanized organ-on-a-chip platform; expected to drive "significant double-digit growth" with high gross margins.
  • Synergy: Complements multi-omic, spatial, and structural biology; addresses drug toxicity translation challenges.
• Atenaeary Technologies:
  • Partnership: Strategic collaboration and minority investment in self-driving labs/agentic AI chemistry R&D; integrated workflows launched in Boston (2026).

Market and Competitive Outlook:

• AI & Semiconductors: Semi-metrology order growth driven by AI infrastructure; industry expected to "hum along with very fast growth rates" in 2027.
• Pharma/Biopharma: CapEx-heavy drug discovery trends are "good" despite quarterly fluctuations; automation and software tools seeing solid demand.
• Academic/Government: "Pent-up demand" for deeper biology tools (proteomics, spatial biology) is driving orders despite federal funding uncertainty; U.S. AcaGov bookings expected to recover further in 2027.
• China: Strong order trends expected to persist in Q4 2026; durability into 2027 considered probable though difficult to predict beyond a few quarters.
• Competitive Positioning: Bruker positioned to capture "deeper biology" market share as customers move from "scratching the surface" to "deep disease biology" insights required for frontier AI models.

Macro / Industry Outlook:

• Currency: USD strengthening expected to result in neutral to slightly negative reported revenue impact for FY2026; FX headwinds expected to diminish.
• U.S. Politics: Midterm election results ("blue wave") speculated to potentially bode well for U.S. AcaGov funding in FY27.
• Geopolitics/Supply Chain: No major anticipated disruptions; semi-con metrology industry described as "extremely well managed" with predictable lead times (typically no delays >1 quarter).
• Funding Dynamics: Shift in AcaGov funding from "Department of Chemistry" needs to "cancer/neurodegeneration/autoimmunity" focus at academic medical centers; reliance on state/philanthropic funding increasing.

Strategic Initiatives:

• M&A: Completed acquisition of MIMETAS (organ-on-a-chip); completed smaller bolt-on acquisitions in metagenomic sequencing and enrichment tech.
• M&A Strategy: Now have capacity for M&A below leverage targets; disciplined approach required to maintain EPS accretion.
• Cost Discipline: Cost-saving actions "mostly" kicked in during Q3 2026 (previously expected in Q4 2025); compounding effects expected to drive Q4 2026 and FY2027 margin expansion.
• Product Launches: WAVE product (antibiotic testing) targeting Q4 2026/Q1 2027 FDA clearance.
• Capacity: Focus on high-margin deep tech orders with longer conversion times to drive future growth.

Risks and Headwinds to Outlook:

• Execution Risks: Customer site readiness issues (uncertainty of +/- $20M/quarter) and supplier execution could delay bookings/conversion.
• Macro/Policy: U.S. AcaGov funding remains subject to lack of conviction and late budget flushes; political uncertainty regarding future Congress/President.
• China Uncertainty: Difficulty predicting China market trends beyond 1–2 quarters.
• Conversion Lag: Semi-metrology and NMR orders have long conversion times (6–12+ months) before revenue recognition.
• Market Fluctuations: Quarterly volatility in AcaGov and Biopharma bookings expected to continue.
• Geopolitics: Potential risks related to tariffs, war/blockades, and supply chain disruptions noted in safe harbor (specific 2026/2027 impacts not quantified).

Management Tone on the Future:

• Confidence Level: High confidence in FY2026 margin expansion and EPS growth; "prudent" but de-risked view on Q4 2026 performance.
• Outlook Shift: Management notes significant improvement in market recovery and booking trends compared to prior quarters; acknowledges 2026 is a "transition year" but expects FY2027 to return to "typical" Bruker growth (200–300 bps above market).
• Guidance Philosophy: Committed to double-digit EPS growth in 2027; cautious about providing specific 2027 guidance numbers due to dynamic timing and historical "unexpected events," preferring to guide in Feb 2027.
• Hedges: Explicitly states 2026 Q4 is "not a shoo-in" and revenue ramp remains subject to risk, despite being "achievable."

Miscellaneous:

• Goodwill Impairment: Non-cash goodwill impairment of ~$175M recorded in Q3 2026 related to Bruker Spatial Biology (GAAP loss of $0.81/share vs. Non-GAAP EPS of $0.56/share).
• Leverage: Net leverage ratio of 2.4x as of Sept 30, 2026; now below previously communicated target, enabling M&A flexibility.
• Share Count: Weighted average diluted shares outstanding were 153.2M in Q3 2026 (up 1.2M from Q3 2025).
• Mix Drivers: Significant mix improvement in NMR and optical microscopy businesses in Q3 2026 contributed ~90 bps to margin.